Lord O'Shaughnessy
Medicines and Healthcare products Regulatory Agency · GBR
Track record: No forecast checked yet (3 not due, 0 being checked).
3forecasts & commitments on the record
100%can be checked as stated
36average ambiguity (0-100)
0goalpost moves recorded
0confirmed U-turns
Timeline
came true partly did not not due / being checked / too vague
Calibration score: shown after 10 checked forecasts with a stated likelihood (now 0).
How they speak about the future: based on data 3.
Kinds of claim: mixed claim 2, forecast 1.
In the nine words
How to read this
Each box is one sentence a public figure or institution said about the future, word for word, with a link to the official text. Can be checked means it names what will happen, by when, and how likely - so it can be compared with official figures later. Too vague to check means it does not. Ambiguity (0-100) is how many different ways the sentence can be read. When the date passes, the forecast is compared with official data and marked came true, partly or did not come true. Labels judge the sentence, never the person. Full guide and glossary.On the record (3)
To underline our commitment, I am pleased to announce today that the Department of Business, Energy & Industrial Strategy and the Department of Health will be providing up to £86 million to support innovators in getting life saving products to patients faster and more efficiently.
Finally, we will support the NHS to adopt and integrate these new technologies into everyday practice through a £6 million Pathway Transformation Fund.
First, we shall establish a £35 million Digital Health Technology Catalyst which will match fund the development of modern day digital solutions for the NHS.
Also said - not checkable as stated (10 newest)
Remarks about the future with no date, figure or likelihood that could be checked. They are kept on the record and shown here, but not scored.
Without the active participation of young people, we will not be successful in achieving the Sustainable Development Goals.
Second: the UK will continue to play a leading role promoting and ensuring public health – both in Europe and around the world
We will also be ambitious in pursuing new trading relationships globally, to ensure that medical devices developed and manufactured in the UK can be exported to all corners of the planet.
I want to assure you that as the Brexit process progresses, we will continue to work closely with industry and trade bodies, including the ABHI, to plan our policy for a prosperous future as a great, global trading nation.
We urge the EU to respond positively to the principles in our recent position paper on the availability of goods in the UK and EU markets – and prevent the risk of disruption that could negatively affect patients in the UK and across Europe.
However, as with other departments, we will be prepared for both a negotiated settlement but also for the unlikely scenario in which no mutually satisfactory agreement can be reached.
We will support global initiatives like the Medical Devices Single Audit Programme, which aims to minimise duplicative regulatory inspections of individual manufacturers – which burden industry without providing any real additional value.
Second: the UK will continue to play a leading role promoting and ensuring public health – both in Europe and around the world; and
We will also be ambitious in pursuing new trading relationships globally, to ensure that pharmaceutical products developed and manufactured in the UK can be exported to all corners of the planet.
I want to assure you that as the Brexit process progresses, we will continue to work closely with industry and trade bodies, including the BIA, to plan our policy for a prosperous future as a great, global trading nation.